Methods of Performing Neutron Capture Therapy

Abstract

Biodegradable Periodic Mesoporous Organosilica (BPMO) nanomaterials and methods of making BPMOs loaded with Neutron Capture Agents are disclosed herein. Consequently, the BPMOs loaded with Neutron Capture Agents provide a method of treating cancer, immunological disorders and other disease by utilizing a Neutron Capture Therapy modality.

1 ) A method of performing neutron capture therapy in the treatment of human cancer comprising:
 a) loading a biodegradable periodic mesoporous organosilica (BPMO) nanomaterial with neutron capture agent, wherein the BPMO is modified with a disulfide bond, a tetrasulfide bond, or a protease sensitive bond;   b) administering the loaded BPMO into a human cancer tumor, whereby said loaded BPMO accumulates into a human cancer tumor cell; and   c) irradiating the loaded BPMO with neutrons.   
     
     
         2 ) The method of  claim 1 , whereby the neutron capture agent comprises the Boron isotope  10 B or a derivative thereof. 
     
     
         3 ) The method of  claim 1 , wherein the neutron capture agent comprises  10 B-4 borono L-phenylalanine ( 10 BPA). 
     
     
         4 ) The method of  claim 1 , whereby the neutron capture agent comprises the Lithium isotope  6 Li or a derivative thereof. 
     
     
         5 ) The method of  claim 1 , whereby the neutron capture agent comprises the Cadmium isotope  113 Cd or a derivative thereof. 
     
     
         6 ) The method of  claim 1 , whereby the neutron capture agent comprises the Samarium isotope  149 Sm or a derivative thereof. 
     
     
         7 ) The method of  claim 1 , whereby the neutron capture agent comprises the Gadolinium isotope  157 Gd or a derivative thereof. 
     
     
         8 ) The method of  claim 1 , whereby the neutron capture agent comprises the Helium isotope  3 He or a derivative thereof. 
     
     
         9 ) The method of  claim 1 , whereby the neutron capture agent comprises an isotope of Au or a derivative thereof. 
     
     
         10 ) The method of  claim 1 , wherein the neutron capture therapy is administered as a monotherapy. 
     
     
         11 ) A method of performing neutron capture therapy in the treatment of human cancer comprising:
 a) loading a biodegradable periodic mesoporous organosilica (BPMO) nanomaterial with neutron capture agent, wherein the BPMO is modified with a disulfide bond, a tetrasulfide bond, or a protease sensitive bond and wherein the BPMO surface is modified with a phosphonate and diol;   b) administering the loaded BPMO into a human cancer tumor, whereby said loaded BPMO accumulates into a human cancer tumor cell; and   c) irradiating the loaded BPMO with neutrons.   
     
     
         12 ) The method of  claim 11 , whereby the neutron capture agent comprises the Boron isotope  10 B or a derivative thereof. 
     
     
         13 ) The method of  claim 11 , wherein the neutron capture agent comprises  10 B-4 borono L-phenylalanine ( 10 BPA). 
     
     
         14 ) The method of  claim 11 , whereby the neutron capture agent comprises the Lithium isotope  6 Li or a derivative thereof. 
     
     
         15 ) The method of  claim 11 , whereby the neutron capture agent comprises the Cadmium isotope  113 Cd or a derivative thereof. 
     
     
         16 ) The method of  claim 11 , whereby the neutron capture agent comprises the Samarium isotope  149 Sm or a derivative thereof. 
     
     
         17 ) The method of  claim 11 , whereby the neutron capture agent comprises the Gadolinium isotope  157 Gd or a derivative thereof. 
     
     
         18 ) The method of  claim 11 , whereby the neutron capture agent comprises the Helium isotope  3 He or a derivative thereof. 
     
     
         19 ) The method of  claim 11 , whereby the neutron capture agent comprises an isotope of Au or a derivative thereof. 
     
     
         20 ) The method of  claim 11 , wherein the neutron capture therapy is administered as a monotherapy.